APA (7th ed.) Citation

Preusser, M., Silvani, A., Le Rhun, E., Soffietti, R., Lombardi, G., Sepulveda, J. M., . . . Wick, W. (2022). Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). Neuro-Oncology, 24(5), . https://doi.org/10.1093/neuonc/noab243

Chicago Style (17th ed.) Citation

Preusser, Matthias, et al. "Trabectedin for Recurrent WHO Grade 2 or 3 Meningioma: A Randomized Phase II Study of the EORTC Brain Tumor Group (EORTC-1320-BTG)." Neuro-Oncology 24, no. 5 (2022). https://doi.org/10.1093/neuonc/noab243.

MLA (9th ed.) Citation

Preusser, Matthias, et al. "Trabectedin for Recurrent WHO Grade 2 or 3 Meningioma: A Randomized Phase II Study of the EORTC Brain Tumor Group (EORTC-1320-BTG)." Neuro-Oncology, vol. 24, no. 5, 2022, https://doi.org/10.1093/neuonc/noab243.